Annual core operating profit increased in 2024 for British pharmaceutical company GSK compared to 2023, the company reported ...

The execs at Haleon, a huge multinational consumer products company, ought to take a good look in the mirror. That is, unless ...

When Bombay DC revamped the Aquaguard logo, it realised that consumers associated ... way that they wouldn’t have in the past. Take the GSK rebrand in 2022. Ten, or 20 years ago, nobody would ...

With Forbion and General Atlantic leading a round that also involved RA Capital Management, Orbimed, Logos Capital ... focused company was scooped up by GSK just 77 days after launching.

Khurem Farooq, formerly chief executive of Aiolos Bio and Gyroscope Therapeutics prior to their respective acquisitions by GSK and Novartis ... OrbiMed, Logos Capital, Lilly Asia Ventures ...

Barclays analyst Emily Field maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK PLC closed 24.32% short of its 52-week high of £18.24, which the company achieved on May 16th.

European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.